EP
ADCT icon

Essential Partners’s ADC Therapeutics ADCT Stock Holding History

Essential Partners’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278 Buy
260
+236
+983% +$688 ﹤0.01% 2582
2026
Q1 		$90 Sell
24
-11
-31% -$43 ﹤0.01% 2731
2025
Q4 		$124 Buy
35
+11
+46% +$45 ﹤0.01% 2516
2025
Q3 		$96 Hold
24
– – ﹤0.01% 2497
2025
Q2 		$64 Buy
+24
New +$50 ﹤0.01% 2123

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Essential Partners's ADCT Position: Q2 2026 in Review

Essential Partners increased its ADC Therapeutics (ADCT) stake by 983% in Q2 2026, buying an estimated $688 and bringing the position to 260 shares worth $278. The position accounts for ﹤0.01% of the portfolio, ranked #2582.

Essential Partners first reported a position in ADCT in Q2 2025 and has held it in 5 quarters since. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Essential Partners held 260 shares of ADC Therapeutics worth $278 as of Q2 2026.
  • Essential Partners bought 236 ADC Therapeutics shares in Q2 2026, an estimated $688.
  • ADC Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2582 holding.
  • Essential Partners first reported a position in ADC Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.